ClinicalTrials.gg
CompletedNCT04793295Updated May 15, 2023

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

A Phase 1 interventional study of MT-7117 in Healthy Subjects, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Study is to investigate drug levels in the blood after taking single or multiple doses of the study drug, MT-7117, in healthy adults when taken together with another drug. This study will also look at the safety and the body's ability to tolerate MT-7117

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma America Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Subjects will be eligible for inclusion in the study if they meet all of the following criteria:

  1. Able and willing to provide written to participate in this study after reading the participant information sheet and Informed Consent Form (ICF) and having the opportunity to discuss the study with the Investigator or designee.
  2. Male and female subjects, self-reporting as white, 18-55 years of age, inclusive, at the time of signing the ICF.
  3. Subjects must weigh at least 50 kg (110 pounds) and have a 18-30 kg/m2, inclusive, at Screening and on Day -1.
  4. Female subjects must not be lactating, and women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 24 hours prior to receiving the first dose of IMP or IMP Test Products.
  5. Female subjects of childbearing potential and male subjects with a partner of childbearing potential must agree to use 2 effective methods of (in female subjects, one method must be highly effective). Full details of contraception in Section 4.6.5.
  6. In the Investigator's opinion, the subject must be able to understand the nature of the study and any risks involved in participation and be willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion Criteria: Any subject meeting any of the following criteria will not qualify for enrolment in the study:

  1. Presence or history of any hepatobiliary disease at Screening, determined by the Investigator after discussion with the Sponsor's Responsible Physician. Current, or history of, clinically significant (in the opinion of the Investigator AND Sponsor's Responsible Physician) neurological conditions, endocrine, thyroid, respiratory, gastrointestinal, renal, or cardiovascular disease, or history (within the last 2 years) of any clinically significant psychiatric/psychotic illness disorder (including anxiety, depression, and reactive depression).
  2. Clinically relevant abnormal medical history, physical findings, or laboratory values at Screening or Day-1 that could interfere with the objectives of the study or the safety of the subjects, in the opinion of the Investigator.
  3. A history of gastrointestinal surgery known to affect the absorption, metabolism, or excretion of the IMP or IMP Test Products such as bariatric surgery or removal of part of the bowel. A history of appendicectomy and hernia repair/herniorrhaphy/hernioplasty is permitted for inclusion in the study.
  4. Family history of long or short syndrome, hypokalemia, syncope, or Torsades de Pointes.
  5. Clinically significant 12-lead (ECG) abnormalities, including subjects with corrected QC interval (QTc) using Fridericia's formula >450 ms (male) and >470 ms (female), at Screening or Day -1. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  6. (AST) or alanine aminotransferase (ALT) 1.5 the (ULN) reference range, or ≥ 1.5 ULN at screening or Day-1. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  7. Systolic blood pressure outside the range of 90-145 mmHg, diastolic blood pressure outside the range of 50-95 mmHg, or pulse rate outside the range of 50-100 bpm, taken in the supine position at Screening or Day -1. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  8. Receipt of any prescribed of nonprescribed systemic or topical medication within 30 days (or, if relevant, 5 half-lives, whichever is longer) prior to the first dose of study drugs unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.

    1. Occasional use of paracetamol (acetaminophen) for mild analgesia is permitted.
    2. Vitamins and herbal supplements are not permitted 14 days prior to dosing
  9. Presence or history of severe adverse reaction or allergy to food or any drug or or other allergy that is of clinical significance to the study drugs.
  10. Previous receipt of MT-7117.
  11. First-degree relative with a history of familial melanoma.
  12. Previous use of afamelanotide or melanotan.
  13. Female subjects planning to donate eggs (during the study and for 3 months after the last visit).
  14. Positive test for surface antigen, hepatitis B core antibody, antibody, or (HIV) 1 or HIV 2 antibodies at Screening.
  15. Presence or history of drug abuse (as defined by criteria), or a positive urine test for drugs of abuse at Screening or Day -1.
  16. Presence or history (in the last 2 years) of alcohol abuse or excessive alcohol consumption, defined as subjects who regularly, or on average, drink more than 21 units (168 g) for males or 14 units (112 g) for females, of alcohol per week (1 unit is equivalent to 8 g of alcohol).
  17. Use of tobacco or nicotine-containing products (snuff, chewing tobacco, cigarettes, cigars, pipes, e-cigarettes, or nicotine replacement products) within 3 months prior to dosing, or a positive urine cotinine test at Screening or Day -1.
  18. Consumption of food or drink containing oranges, grapefruit, liquorice, or cranberry within the 7 days prior to the first dose of study drug.
  19. Subjects who are not willing to abstain from consumption of caffeine and methylxanthine (e.g., coffee, tea, cola, energy drinks, or chocolates) in the 48 hours before Day -1 until completion of the post-treatment assessments and in the 48 hours before the Follow-up/End of Study Visit.
  20. Donation of 1 or more units of blood (450 mL) in the 3 months prior to Screening, plasma in the 7 days prior to Screening, in the 6 weeks prior to Screening, or the intention to donate blood within 3 months after the last scheduled visit.
  21. Heavy physical training, labor, or excessive exercise (e.g., long-distance running, weightlifting, or any physical activity to which the subject is not accustomed) from 3 days before the administration of study drugs.
  22. Participation in more than 3 clinical studies* involving administration of an IMP in the previous year, or any study* involving administration of an IMP within 8 weeks (or, if relevant, 5 half-lives, whichever is longer) prior to the first dose of study drug.

    *Disregarding any study Follow-up Periods.

  23. Subjects with the presence of a skin lesion suspicious for dysplastic nevus or a history of proven dysplastic nevus.
  24. Subjects who have any active (including melanoma) or history of significant malignancy (including melanoma).
  25. Subjects who have had Coronavirus Disease 2019 (COVID-19) in the 3 months prior to Screening; or suspected active COVID-19 infection, a positive COVID-19 test, contact with an individual with known COVID-19, or travel to an area with a high risk of COVID-19 infection within 14 days of Screening.
  26. Subjects that test positive for COVID-19 at Screening (Parts 3 and 4) or Day -1 (Parts 1-4).
  27. Subjects who have received a COVID-19 vaccination within 14 days of Day 1. COVID-19 vaccination is not permitted during the study. Subjects may not take part in the study if they have started but not completed a COVID-19 vaccination course at the time of Screening or Day -1.
  28. Subjects who have a history of major surgery within 3 months of Day 1.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    MT-7117 Drug-drug interaction with test drug 1 and test drug 2

    Drug: MT-7117

  • Experimental
    MT-7117 Drug-drug interaction with test drug 3 and test drug 4

    Drug: MT-7117

  • Experimental
    MT-7117 Drug-drug interaction with test drug 5 and test drug 6

    Drug: MT-7117

  • Experimental
    MT-7117 Drug-drug interaction with test drug 7

    Drug: MT-7117

Interventions

  • MT-7117

    Also known as: Dersimelagon

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  2. Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-∞)

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  3. AUC from time zero to the last measurable concentration (AUC0-last)

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

Secondary outcomes

  1. Time to reach maximum plasma concentration (tmax)

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  2. t1/2

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  3. Apparent oral clearance

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  4. Apparent volume of distribution during the terminal phase after oral administration

    PK parameters of IMP Test Products in the absence and presence of MT-7117 (Parts 1, 2, and 3) and MT-7117 in the absence and presence of test drug 7 (Part 4)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  5. Cmax

    PK parameters of IMP Test Products metabolites in the absence and presence of MT-7117 (Parts 1, 2, and 3)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  6. tmax

    PK parameters of IMP Test Products metabolites in the absence and presence of MT-7117 (Parts 1, 2, and 3)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  7. t1/2

    PK parameters of IMP Test Products metabolites in the absence and presence of MT-7117 (Parts 1, 2, and 3)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  8. AUC0-last

    PK parameters of IMP Test Products metabolites in the absence and presence of MT-7117 (Parts 1, 2, and 3)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  9. AUC0-∞

    PK parameters of IMP Test Products metabolites in the absence and presence of MT-7117 (Parts 1, 2, and 3)

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  10. MT-7117 concentrations in plasma

    Time frame: Part 1 Day 1 to Day 19, Part 2 Day 1 to Day 15, Part 3 Day 1 to Day 17, Part 4 Day 1 to Day 13

  11. Safety and tolerability as measured by incidence of adverse events

    Time frame: Part 1 Day -1 to Day 25, Part 2 Day -1 to Day 21, Part 3 Day -1 to Day 23, Part 4 Day -1 to Day 19

07

Study locations

2 sites
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Feb 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 11, 2021
StartActual
Mar 23, 2021
Primary completionActual
Feb 4, 2022
CompletionActual
Feb 4, 2022
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04793295
Responsible party
Sponsor
First posted
Mar 11, 2021
Start date
Mar 23, 2021
Primary completion
Feb 4, 2022
Completion
Feb 4, 2022
Last update
May 15, 2023

Study contacts

Head of Medical Science
study director · Mitsubishi Tanabe Pharma America Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion